Abstracts tagged "Lupus nephritis"

Abstract Number: 2550 • ACR Convergence 2024
Infiltrating and Resident Macrophages in Lupus Nephritis: Scar Associated Macrophage Phagocytic Dysfunction and Fibroblast Activation
Chirag Raparia¹, Paul Hoover², Arnon Arazi³, Nir Hacohen⁴ and Anne Davidson⁵, ¹Donald and Barbara Zucker School of Medicine At Hofstra/Northwell, Shoreham, NY, ²Brigham and Women's Hospital, SWAMPSCOTT, MA, ³Feinstein Institutes for Medical Research, Melrose, MA, ⁴Broad Institute of MIT and Harvard, Boston, MA, ⁵Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Lupus nephritis (LN) is driven by a heterogeneous population of renal macrophages. We have previously reported that the renal macrophage subpopulations are similar in…
Abstract Number: 0008 • ACR Convergence 2024
Preclinical Development and Manufacturability of KYV-201, an Investigational Allogeneic Anti-CD19 Chimeric Antigen Receptor T Cell for the Treatment of Autoimmune Disease
Ashley Mahne¹, Ryan Rodriguez², Jessica Wang¹, Daniel Anaya¹, Joseph K. Cheng¹, Brandon Kwong¹, Jesus Banuelos³, Peter Starokadomskyy³, Soo Park³, Candice Gibson⁴, Shouvonik Sengupta¹, Simone Sandoval¹, Jazmin Bravo³, Jeanne Flandez¹, Shairaz Shah¹, Amanda Goodsell¹, Nicole Khoshnoodi¹, Jennifer Zeng¹, Santiago Foos-Russ¹, Mario Lorente¹, Jennifer Adrian¹, Timothy Klasson¹, Yong Zhang⁵, Jessica Seitzer⁶, Birgit Schultes⁵ and Tom Van Blarcom³, ¹Kyverna Therapeutics, Inc., Emeryville, CA, ²Kyverna Therapeutics, Inc., Emerville, CA, ³Kyverna Therapeutics, Inc., Emeryville, ⁴Kyverna Therapeutics, Inc., Emerybille, ⁵Intellia Therapeutics, Inc., Cambridge, MA, ⁶Intellia Therapeutics, Inc., Cambridge
Background/Purpose: Autologous anti-CD19 chimeric antigen receptor (CAR) T cells show early clinical evidence of safety and efficacy for treating several autoimmune diseases (Müller F. N Engl…
Abstract Number: 0640 • ACR Convergence 2024
7000-Plex Proteomic Screen of Urine for Flare Monitoring and Treatment Response Biomarkers in Active Lupus Nephritis
kamala Vanarsa¹, Yewei Ma², Mohammad Daouk², Vinaika Maruvada², Ramesh Saxena³ and Chandra Mohan⁴, ¹University of Houston, houstton, ²University of Houston, Houston, ³UT Southwestern Medical Center, Dallas, ⁴University of Houston, Houston, TX
Background/Purpose: Lupus nephritis (LN) is a major cause of morbidity and mortality in patients with lupus. Since the kidney biopsy is invasive, better, more predictive…
Abstract Number: 0811 • ACR Convergence 2024
High-Throughput Proteomic Profiling of Longitudinal Serum Samples to Predict Treatment Response in Lupus Nephritis
Benjamin Jones¹, Rufei Lu², Andrea Fava³, Peter Izmirly⁴, Jennifer Anolik⁵, Chaim Putterman⁶, David Wofsy⁷, Matthias Kretzler⁸, Celine Berthier⁹, E. Steven Woodle¹⁰, Michael Weisman¹¹, Mariko Ishimori¹², The Accelerating medicines Partnership: RA/SLE Network¹³, Betty Diamond¹⁴, Jill Buyon¹⁵, Michelle Petri¹⁶, Judith James¹³ and Joel Guthridge¹³, ¹Oklahoma State University, Oklahoma City, OK, ²University of California San Francisco, San Bruno, CA, ³Johns Hopkins University, Baltimore, MD, ⁴New York University Grossman School of Medicine, New York, NY, ⁵University of Rochester Medical Center, Rochester, NY, ⁶Albert Einstein College of Medicine, Safed, Israel, ⁷University of California San Francisco, SF, CA, ⁸University of Michigan, Ann Arbor, MI, USA, Ann Arbor, MI, ⁹University of Michigan, Ann Arbor, MI, ¹⁰University of Cincinnati College of Medicine, Cincinnati, OH, USA, Cinncinnati, OH, ¹¹Stanford University, Los Angeles, CA, ¹²Cedars-Sinai Health System, Los Angeles, CA, ¹³Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁴The Feinstein Institutes for Medical Research, Manhasset, NY, ¹⁵NYU Grossman School of Medicine, New York, NY, ¹⁶Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Lupus nephritis (LN) can lead to severe morbidity and early mortality in SLE patients. While therapeutic options for LN have improved, they are not…
Abstract Number: 1536 • ACR Convergence 2024
Prescription Rates of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Lupus Nephritis: A Comparative Study Across Specialties
JM JANSZ¹, EA Troy², WL Galanter³, Elaine Adams⁴, Nadera Sweiss⁵ and HJ CHANG⁶, ¹University of Illinois at Chicago, Chicago, IL, ²University of Illinois at Chicago, Woodridge, IL, ³University of Illinois at Chicago; Jesse Brown VA Medical Center, CHICAGO, IL, ⁴Jesse Brown VA Medical Center, La Grange, IL, ⁵University of IL, Chicago, IL, ⁶RHEUMATOLOGIST, CHICAGO, IL
Background/Purpose: Lupus nephritis is a well-known and severe complication in patients with systemic lupus erythematosus (SLE) that can lead to significant morbidity and mortality. Angiotensin-converting…
Abstract Number: 1870 • ACR Convergence 2024
Costs and Healthcare Resource Utilization Associated with Inpatient and Day Hospitalizations of Patients with Lupus and Psychiatric Manifestations in France
Nicoleta Petrica¹, Nathan Cohen¹, Maria Pini¹, Minjee Park², Mathieu Rosé³ and Jean-Francois Ricci², ¹Alira Health, Paris, France, ²Alira Health, Basel, Switzerland, ³Alira Health, Barcelone, Spain
Background/Purpose: Lupus, a rare chronic autoimmune disorder, severely impacts patients' quality of life, productivity, and survival, placing a heavy burden on the healthcare system. Up…
Abstract Number: 2575 • ACR Convergence 2024
Can Immunosuppressive Therapy Be Safely Discontinued in Patients with Lupus Nephritis?
Paola Vidal¹, Javier Narvaez-García², Francesc-Xavier Fulladosa², Francesca Mitjavila², olga Capdevila², Pol Maymó³, Judith Palacios⁴ and Joan Miquel Nolla², ¹Hospital Universtiario de Bellvitge, Barcelona, Spain, ²Hospital Universitario de Bellvitge, Barcelona, Spain, ³Hospital Universitario de Bellvitge., Barcelona, Spain, ⁴Bellvitge University Hospital, L'Hospitalet de Llobregat, Catalonia, Spain
Background/Purpose: The latest guidelines for managing lupus nephritis (LN), including the 2024 KDIGO guidelines and the 2019 EULAR/ERA-EDTA update, recommend a minimum immunosuppression (IS) duration…
Abstract Number: 0018 • ACR Convergence 2024
Preclinical Analysisof CB-010, an Allogeneic anti-CD19CAR-T Cell Therapywith a PD-1 Knockout, for the Treatment of Patients with Refractory Systemic Lupus Erythematosus (SLE)
Elizabeth Garner, George Kwong, Tristan W Fowler, Heinrich Kufeldt, Brian Kerfs, Julie Kim, Art Aviles, Lynne Alexander, Franco Davi, Chris Holland, Jean-Yves Maziere, Ashraf Garrett, Mara Bryan, Linh Chu, Sarbani Bhaduri, Michele Gerber, Elaine Alambra, Justin Skoble, Tom Kochy, Tonia Nesheiwat, Socorro Portella, Enrique Zudaire and Steven B Kanner, Caribou Biosciences, Berkeley, CA
Background/Purpose: Autologous CD19-directed CAR-T cell therapy has been shown to eradicate aberrant B cells leading to durable clinical responses in SLE patients (Müller 2024; Wang 2024). However, autologous CAR-T cell…
Abstract Number: 0646 • ACR Convergence 2024
Chart Audit of over 1,000 SLE Patients Reveals Biologic Treatment Choice Driven by Disease Manifestations
Maxine Yarnall¹, Ryan Rex² and Sawyer May¹, ¹Spherix Global Insights, Exton, PA, ²Spherix Global Insights, Chester Springs, PA
Background/Purpose: To better understand how US rheumatologists utilize biologics in the management of SLE, especially among those with cutaneous manifestations. No medication is currently FDA-approved…
Abstract Number: 0812 • ACR Convergence 2024
A Human Gut Pathobiont Drives Platelet Activation with Microparticle Release and NETosis During Lupus Nephritis Flares
Abhimanyu Amarnani¹, Cristobal Rivera-Martinez¹, Marc Scherlinger², Doua Azzouz¹, Andy Lee¹, Kate Trujillo¹, MacIntosh Cornwell¹, Tyler Weinstein¹, Tatiana Borja³, Bharati Matta⁴, Sharon Chung⁵, Laura Cooney⁶, Uzair Chaudhary¹, Steven Medvedovsky¹, Peter Izmirly¹, Jill Buyon¹, Patrick Blanco⁷, Betsy Barnes⁸, Bhama Ramkhelawon¹, Kelly Ruggles⁹ and Gregg Silverman¹, ¹New York University Grossman School of Medicine, New York, NY, ²Strasbourg University Hospital, Strasbourg, France, ³Feinstein Institutes for Medical Research, New York, NY, ⁴The Feinstein Institutes for Medical Research, Manhasset, NY, ⁵University of California, San Francisco and Immune Tolerance Network, San Francsico, ⁶University of Michigan and Immune Tolerance Network, Ann Arbor, MI, ⁷UMR_CNRS 5164 Immunoconcept, BORDEAUX CEDEX, France, ⁸Feinstein Institutes for Medical Science, Manhasset, NY, ⁹NYU Grossman School of Medicine, Brooklyn, NY
Background/Purpose: SLE is a leading cause of premature death, often from severe complications including lupus nephritis (LN), especially in disadvantaged groups. Despite advances in treatment,…
Abstract Number: 1538 • ACR Convergence 2024
Patient Reported Outcomes Analyses from AURORA 1 Clinical Trial: Lupus Impact Tracker and LupusPRO
Meenakshi Jolly¹, Matt Truman², Ronald Flauto³ and Kathryn Dao⁴, ¹Rush University, Chicago, IL, ²Aurinia Pharmaceuticals, Victoria, BC, Canada, ³Aurinia Pharmaceuticals, Rockville, MD, ⁴Rheum101, Rockville, MD
Background/Purpose: Voclosporin used in addition to Mycophenolate Mofetil and low dose oral steroids in patients with active Lupus Nephritis (LN) was found to be superior…
Abstract Number: 1873 • ACR Convergence 2024
Race/Ethnicity and Household Income at the County Level Interacts with the Association of Urbanicity and Lupus Nephritis Mortality
Snehin Rajkumar¹, Eric Yen² and Ram Singh³, ¹UCLA David Geffen School of Medicine, Irvine, CA, ²UCLA, Los Angeles, CA, ³UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: The reasons underlying substantial variation in lupus nephritis (LN) deaths by race/ethnicity remain largely unknown. There are no large population-based studies focused on the…
Abstract Number: 2576 • ACR Convergence 2024
Glucagon-Like Peptide-1 Receptor Agonist Use and the Risk of Adverse Cardiac and Kidney Outcomes Among Patients with Systemic Lupus Erythematosus and Lupus Nephritis
April Jorge¹, Aakash Patel¹, Baijun Zhou², Yuqing Zhang³ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School; The Mongan Institute, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital, Lexington, MA
Background/Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are hypoglycemic agents with well-established cardioprotective properties and emerging data for kidney-protective benefits in patients with type 2 diabetes…
Abstract Number: 0593 • ACR Convergence 2023
Lupus Nephritis of the Spanish National Registry of Belimumab in Patients with Systemic Lupus Erythematosus
María laiño¹, Monica Enguita², Pablo Navarro³, Javier Loricera⁴, Angel Garcia-Aparicio⁵, Carmen Lasa⁶, Vanesa Calvo Río⁷, Adela Gallego⁸, Clara Moriano Morales⁹, Javier Narvaez¹⁰, MARIA IRENE CARRION BARBERA¹¹, Jordi Camins-Fàbregas¹², Joaquin Maria Belzunegui Otano¹³, Ana Urruticoechea¹⁴, Leticia del Olmo Perez¹⁵, Santos Castañeda¹⁶, Patricia Quiroga¹⁶, Ivette Casafont-Sole¹⁷, Juan Ramon De Dios Jimenez De Aber¹⁸, Marta López¹⁹, Judit Font Urgelles²⁰, Rafaela Ortega Castro²¹, Marta Garijo Bufort²², Jorge Juan Fragio²³, Ignacio Vázquez²⁴, Mamen Ortega²⁵, Aaron Fariñas²⁶, Cilia Peralta²⁷, Juan María Blanco²⁸, Sergi Heredia Martin²⁹, Maria Valvanera Pinillos³⁰, Eztizen Labrador-Sánchez³¹, Piter Jose Cossio Jimenez³², Carlos Vazquez Galeano³³ and Vicente Aldasoro¹, ¹Hospital Universitario de Navarra, Pamplona, Spain, ²Navarrabiomed-Unidad de Metodología, Pamplona, Spain, ³Rheumatology, Hospial Universitario Puerta de Hierro, Majadahonda, Spain, ⁴Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Hospital Universitario de Toledo, Toledo, Spain, ⁶Hospital Universitario Marqués de Valdecilla, IDIVAL., La Cavada, Spain, ⁷Valdecilla Hospital, Santander, Spain, ⁸Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ⁹Rheumatology, Hospital Universitario de León, León, Spain, ¹⁰Hospital Universitario de Bellvitge, Barcelona, Spain, ¹¹Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ¹²Hospital General de Granollers, Granollers, Spain, ¹³University Hospital Donostia, Donostia-San Sebasti, Spain, ¹⁴Hospital Can Misses, Ibiza, Spain, ¹⁵Hospital Nuestra Señora del Prado, Talavera de la Reina, Spain, ¹⁶Hospital Universitario de la Princesa, Madrid, Spain, ¹⁷Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁸Hospital de Araba, Alava, Spain, ¹⁹Hospital Universitario Arava, Pamplona, Spain, ²⁰Hospital Universitario German Trias i Pujol,, Badalona, Spain, ²¹Hospital Reina Sofía, Cordoba, Spain, ²²Hospital de Sagunto, Valencia, Spain, ²³Hospital General Universitario Valencia, Valencia, Spain, ²⁴H. U. Dr. Peset, Valencia, Spain, ²⁵Hospital Universitario de Getafe, Getafe, Spain, ²⁶Complejo Asistencial Universitario de Palencia, Palencia, Spain, ²⁷Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ²⁸Hospital Universitario de Basurto, Bilbao, Spain, ²⁹Complex Hospitalari Moisès Broggi, Barcelona, Spain, ³⁰Hospital Universitario San Pedro, Logroño, Spain, ³¹Hospital Universitario San Pedro, Laguardia, Spain, ³²HOSPITAL REINA SOFIA, Tudela, Spain, ³³ZARAGOZA, Madrid, Spain
Background/Purpose: Belimumab (BLM) is a B-cell stimulating factor (BlyS) monoclonal antibody, approved in 2022 for the treatment of lupus nephritis (NL) and since 2011 for…
Abstract Number: 0911 • ACR Convergence 2023
Spatial Transcriptomics Reveals Normal-density and Low-density Neutrophils Are More Prevalent Than Macrophages in Lupus Nephritis Glomeruli, and Urine DNA Methylation Analyses Capture Both Myeloid Populations
Sladjana Skopelja-Gardner¹, Joshua Skydel², Alecia Roy³, Brenna Kerin³, James Whitley³, Fred Kolling⁴, Noelle Kosarek⁴, Michelle Petri⁵, Andrea Fava⁶, Lucas Salas⁷ and Christopher Burns³, ¹Department of Medicine, Dartmouth Hitchcock Medical Center, Geisel School of Medicine at Dartmouth, Lebanon, NH, ²Dartmouth-Hitchcock Medical Center, Lebanon, NH, ³Dartmouth Hitchcock Medical Center, Lebanon, NH, ⁴Geisel School of Medicine at Dartmouth, Hanover, NH, ⁵Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁶Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Department of Epidemiology, Geisel School of Medicine at Dartmouth, Lebanon, NH
Background/Purpose: Despite compelling evidence that normal-density (NDN) and low-density neutrophils (LDN) are activated in the blood of lupus patients, their role in lupus nephritis (LN)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].